Johnson & Johnson $JNJ Shares Sold by Van Lanschot Kempen Investment Management N.V.

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Van Lanschot Kempen Investment Management N.V. decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 15.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 904,093 shares of the company's stock after selling 170,315 shares during the quarter. Johnson & Johnson accounts for about 1.6% of Van Lanschot Kempen Investment Management N.V.'s investment portfolio, making the stock its 19th largest holding. Van Lanschot Kempen Investment Management N.V.'s holdings in Johnson & Johnson were worth $149,935,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of JNJ. Highline Wealth Partners LLC grew its position in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $47,000. von Borstel & Associates Inc. purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $49,000. Capital A Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $50,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $52,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on JNJ shares. Guggenheim reiterated a "neutral" rating and set a $167.00 target price (up from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Barclays raised their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Finally, Morgan Stanley raised their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Stock Performance

JNJ stock traded up $0.7890 during mid-day trading on Wednesday, reaching $178.5890. The company had a trading volume of 9,028,878 shares, compared to its average volume of 8,462,277. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $430.10 billion, a P/E ratio of 19.10, a P/E/G ratio of 2.26 and a beta of 0.41. Johnson & Johnson has a one year low of $140.68 and a one year high of $180.61. The stock's 50-day simple moving average is $162.13 and its two-hundred day simple moving average is $158.73.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the business posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.